ISTA licenses two ophthalmic products from Senju

By Lisa Kerner

Charlotte, N.C., June 16 - ISTA Pharmaceuticals Inc. said it has exclusively licensed from Senju Pharmaceuticals, Co., Ltd. the North American rights to two new product candidates, iganidipine, a calcium channel blocker, and a new formulation of latanoprost, a prostaglandin.

Iganidipine and latanoprost are both under investigation for the treatment of glaucoma and other ophthalmic applications, according to a company news release.

Under the agreement, for both products ISTA will pay Senju upfront and milestone payments up to $8 million as well as royalties on product sales.

ISTA will complete all development, including clinical trials and submission of New Drug Applications, and all manufacturing, marketing and selling activities.

Senju previously licensed to ISTA certain U.S. rights to Istalol (0.5% timolol maleate ophthalmic solution) for the treatment of glaucoma, Xibrom (0.1% bromfenac sodium ophthalmic solution) for the treatment of ocular inflammation, eye pain and photophobia, and ecabet sodium for the treatment of dry eye syndrome.

Located in Irvine, Calif., ISTA discovers, develops and markets ophthalmic products for serious diseases and conditions.

Japan-based Senju specializes in over-the-counter ophthalmologic products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.